Wednesday, June 10, 2026
← Back to archivePolicy
Policy•STAT News•Jun 9, 2026
Trump administration warns more than 500 hospitals to provide more price information or face fines
background ▾
- •Over 500 hospitals have received formal warnings since April 2025 with penalties escalating to $2M annually for continued non-compliance with price transparency disclosure rules.
- •Texas, Indiana, Florida, Louisiana, and Alabama—predominantly Republican states—represent the highest concentration of non-compliant hospitals, signaling potential political targeting.
- •Hospital industry and healthcare economists question whether publicly disclosed pricing data will meaningfully reduce costs for consumers versus benefit consultants and institutional buyers with analytical infrastructure.
AscensionBaptist Medical Center San AntonioUniversity of Texas MD Anderson Cancer Center
→ Read original articlePolicy•Fierce Pharma•Jun 10, 2026
WuXi AppTec lands on Pentagon blacklist, facing Biosecure ban
background ▾
- •WuXi AppTec's Pentagon blacklist designation under the Biosecure Act could force U.S. pharma/biotech companies to rapidly transition critical outsourced R&D and manufacturing away from the world's largest CRMO, disrupting timelines and increasing costs industry-wide
- •The listing reflects accelerating geopolitical bifurcation of the biotech supply chain and signals that U.S. national security policy will increasingly drive sourcing decisions independent of commercial efficiency
- •Watch for: (1) legal/administrative appeals from WuXi and affected U.S. companies; (2) Biosecure Act implementation timelines and enforcement; (3) alternative CRO capacity constraints as clients scramble to reallocate work
WuXi AppTec
→ Read original articlePolicy•Fierce Pharma•Jun 10, 2026
AstraZeneca reprimanded over LinkedIn likes once again
background ▾
- •AstraZeneca faces its latest reprimand for employee LinkedIn violations, reflecting a persistent compliance gap in social media governance
- •The repeated nature of these violations suggests systemic internal control or training deficiencies that may warrant regulatory or reputational consequences
AstraZeneca
→ Read original articlePolicy•STAT News•Jun 10, 2026
Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72
background ▾
Policy•STAT News•Jun 10, 2026
Opinion: Even in abortion-protecting states, teens face unnecessary barriers to care
background ▾
- •Even in states with constitutional abortion protections, 38 states maintain parental consent/notification laws that create disproportionate barriers for minors, with 7 states requiring both consent and notification
- •Nevada and Colorado legal cases challenging parental involvement laws may set precedents for broader reexamination of adolescent abortion access equity, though outcomes remain uncertain
- •Monitor outcomes of the Nevada case in lower courts and the Colorado OB-GYN lawsuit, as well as implementation of travel restriction laws in the two states that enacted them
Market Access
Market Access•Fierce Biotech•Jun 9, 2026
Fueled by M&A and partnerships, biotech is poised for continued growth: EY
background ▾
- •M&A and partnerships are the primary confidence driver, with $100B deployed in 2025 and accelerating Q1 2026 pace of $36B
- •Chinese biotech now captures ~40% of U.S. biobucks committed annually, increasingly viewed as credible innovation source in advanced modalities (ADCs, bispecifics)
- •Monitor the consolidation trajectory and 'liquidity trap' dynamic—while mega-rounds and revenues climb, total biotech company count is shrinking; sustainability of this growth model remains uncertain amid regulatory and geopolitical pressures
Market Access•Fierce Biotech•Jun 9, 2026
Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal
background ▾
- •Lilly is aggressively building its Alzheimer's portfolio through targeted licensing deals (AlzeCure for $1B potential, AC Immune expansion in April) while managing a pipeline that includes both winners (Kisunla projected at $3.8B by 2033) and failures (eperognastat discontinuation).
- •The heavily backloaded deal structure ($10M upfront, >$1B in milestones) suggests Lilly is betting on ACD860's potential rather than immediate near-term value, indicating the program is likely in early-to-mid stage development with uncertain clinical prospects.
- •Watch for clinical trial initiation/readout for ACD860 and whether Lilly's multi-pronged Alzheimer's strategy (amyloid-targeting Kisunla, tau-targeting programs, and now gamma-secretase modulation) will collectively capture market share as the Alzheimer's market is projected to expand 8-fold by 2034.
Eli LillyAlzeCure PharmaACD860Kisunlaeperognastat
→ Read original articleMarket Access•Fierce Biotech•Jun 9, 2026
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market
background ▾
- •Galmed acquires Colospan's CE-marked CG-100 device and active U.S. pivotal program for $4.5M, aiming to address the substantial quality-of-life and economic burden associated with temporary stomas in colorectal surgery
- •The device technology targets a $6 billion GI diagnostics market, with Galmed positioning this acquisition as a platform-building moment to enter the medical device space
- •Key to watch: timing and outcomes of the U.S. pivotal trial for CG-100 and FDA approval pathway; commercial traction in European market post-CE marking
Galmed PharmaceuticalsColospanCG-100
→ Read original articleMarket Access•Fierce Pharma•Jun 10, 2026
AbbVie’s Skyrizi narrowly slides ahead of J&J’s Tremfya in May drug ad spending rankings
background ▾
- •Most top-10 drug advertisers decreased TV ad spending in May, indicating a seasonal or strategic pullback in DTC promotion across the sector
AbbVieJohnson & JohnsonSkyriziRinvoqTremfya
→ Read original articleMarket Access•Fierce Pharma•Jun 10, 2026
‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness campaign
background ▾
- •BMS is conducting a celebrity-driven patient awareness campaign for multiple myeloma to enhance disease visibility and potentially support uptake of its CELMoD franchise
Bristol Myers SquibbCELMoD
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 10, 2026
Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue
background ▾
- •Riliprubart failed to demonstrate adequate efficacy in treatment-refractory CIDP patients despite showing 87% improvement/stability rates in Phase 2, highlighting a common translational challenge when efficacy observed in midphase studies does not replicate in larger Phase 3 populations
- •The failure strengthens competitive positions for rival programs: Argenx's already-approved Vyvgart Hytrulo and phase 3 C2 inhibitor, and Dianthus's claseprubart (C1 inhibitor in Phase 3), which may now capture market share in the complement-modulation CIDP space
- •Watch for Sanofi's decision on the second Phase 3 trial and potential strategic pivot; continued pipeline setbacks could accelerate portfolio restructuring under new leadership and increase M&A/divestiture risk
SanofiCSL BehringGrifolsriliprubartamlitelimabbalinatunfib
→ Read original articleClinical Trials•STAT News•Jun 9, 2026
Gilead and Merck’s latest trial success and flop
background ▾
- •Gilead and Merck's once-weekly HIV combination pill (islatravir + lenacapavir) met efficacy endpoints in Phase 3, advancing the longer-acting HIV treatment landscape and potentially improving patient adherence versus daily regimens.
- •EVOKE-03 failure signals Trodelvy's limited utility in non-small cell lung cancer despite prior approval in breast cancer, weakening Gilead's cancer portfolio ambitions; Merck's competing TROP-2 antibody (sac-TMT with Kelun) showed superior efficacy in similar settings.
- •Monitor regulatory decisions on the once-weekly HIV pill (timeline unclear) and Gilead's strategic response to Trodelvy failures; track sac-TMT development and competitive landscape for next-generation HIV and lung cancer therapies.
Gilead SciencesMerckGSKislatravirlenacapavirYeztugo
→ Read original articleClinical Trials•Fierce Pharma•Jun 10, 2026
Merck, Gilead score in effort to develop the first weekly HIV pill
background ▾
- •Phase 3 success with once-weekly dosing marks a meaningful shift in HIV treatment convenience, potentially improving real-world adherence compared to daily pills
- •Merck-Gilead partnership demonstrates continued industry focus on long-acting oral antiretrovirals as alternative to injectable cabotegravir/rilpivirine
- •Watch for regulatory submissions and full efficacy/safety data disclosure; competitive landscape includes other long-acting HIV therapies in development
MerckGilead Sciencesislatravirlenacapavir
→ Read original articleClinical Trials•Fierce Biotech•Jun 9, 2026
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program
background ▾
- •Elecoglipron achieved 10.5–11.8% weight loss and 1.9% HbA1c reduction in phase 2b, with Jefferies analysts noting numerically superior efficacy versus other oral small-molecule GLP-1 agonists and 'competitive efficacy with standard tolerability.'
- •AstraZeneca is launching three pivotal programs: Embold (obesity monotherapy), Eluminate (monotherapy and combination with Farxiga in type 2 diabetes), plus long-term cardiovascular and kidney outcomes studies, signaling serious commercial intent.
- •Watch for Embold and Eluminate phase 3 readouts and any competitive positioning updates, particularly as Eli Lilly, Novo Nordisk, and emerging players densify the oral GLP-1 market; AZ's 2031 obesity revenue consensus of $1 billion could face upward or downward revision based on phase 3 success and combination strategy validation.
AstraZenecaCSPC PharmaceuticalEli LillyelecoglipronAZD6234Farxiga
→ Read original article